Acute coronary syndrome during antiretroviral treatment
Keywords:
Acute coronary syndrome, HIV, antiretroviral treatmentAbstract
Aim : The aim of this study is to determine epidemiological, clinical, therapeutic and outcome characteristics of acute coronary syndrome in AIDS patients under HAART.Results- The charts of 5 patients were reviewed. The mean age, at the time of the discovery of HIV infection, was 35 years. Three patients were smokers and one had a family history of diabetes and acute coronary syndrome (ACS). Three patients received 2 nucleoside reverse transcriptase inhibitors (NRTIs) with indinavir. The 2 others received 2 NRTIs with efavirenz with good immunovirologic response. Four patients developed mixed dyslipidemia after an average period of 26 months. Tow patients developed diabetes and one a hypertension. A specific treatment was initiated in all cases. These five patients developed an ACS after respectively 51, 95, 96,103 and 145 months of ART (median=98 months). ACS occurred in 3 patients receiving 2 NRTIs and PI and two others 2 NRTIs with efavirenz. The mean age at the onset of ACS was 46 years. One patient underwent a triple bypass surgery, tow a stenting of the stenotic coronary and the last 2 patients received medical treatment with a good clinical outcome. The PI was replaced by efavirenz in two patients. Four patients had a recurrence of ACS respectively after 2months, 3 months, 12 months, and 62 months after the first episode. The five patients are still followed with good clinical and biological outcome.
Downloads
References
Duong M, Cottin Y, Froidure M et al. Les patients infectés par le virus de l'immunodéficience humaine sous traitement antirétroviral ont-ils un risque cardiovasculaire accru ? Ann Cardiol d'Angeiol 2003; 52: 302-7
Leclercq P, Roudière L et Viard JP. Complications graves des traitements antirétroviraux. Réanimation 2004;13 : 238-48.
Sabin C, Worm SW, Weber R et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371: 1417-26
El Hattaoui, M, Charei N, Boumzebrab D et al. Étude de la prévalence des cardiomyopathies au cours de l'infection VIH : étude prospective de 158 patients VIH. Med Mal Infect 2008 ; 38 : 387-91.
Dau B et Holodniy M. The Relationship between HIV Infection and Cardiovascular Disease. Current Cardiology Reviews 2008 ; 4 : 203-18.
Aim JL, Orlando B, Cantin-Bertaux D et al. Infarctus du myocarde et SIDA Annales françaises d'anesthésie et de réanimation 2002 ; 21: 741-3
Lyonne L, Magimela C, Cormerais L et al. Evénements thromboemboliques à l'ère des trithérapies antirétrovirale. Rev Med Int 2008; 29 : 100-4.
Le Houssine P, Karmochkine M, Ledru F et al. Hypertension artérielle pulmonaire primitive au cours de l'infection par le virus de l'immunodéficience humaine. Etude de neuf observations et revue de la littérature. Rev Med Int 2001; 22:1196-203
Worm SW, Sabin C, Weber R et al. Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. J Infect Dis 2010: 201:318-33.
ositti G, Cassola G, Piscopo R et al. Class of Antiretroviral Drugs and the Risk of Myocardial Infarction. N Engl J Med 2007; 356: 1723-35.
Leclercq P. Préoccupations cardiovasculaires. Med Mal Infect 2009; 39: 10-4
Paton P, Tabib A, Loire R et al. Coronary artery lesions and human immunodeficiency virus infection. Res Virol 1993; 144:225-31.
Bozzette SA, Ake CF, Tam HK et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 8:702-10.
Joussein-Remacle S, Delarche N, Bader H et al. Facteurs de risque de l'infarctus du myocarde du sujet jeune : registre prospectif sur un an. Ann Cardiol Angeiol 2006 ; 55 : 204-9.
